Government of Saskatchewan ministries, Crown corporations and organizations are implementing contingency plans to minimize the impacts of postal service disruption.
Les ministères, sociétés d’État et organismes du gouvernement de la Saskatchewan mettent en œuvre des plans d’urgence (en anglais) visant à réduire les répercussions de l’interruption du service des postes.
Google Translate Disclaimer
A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:
Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.
Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).
Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.
Released on August 13, 2024
The Government of Saskatchewan, Saskatchewan Health Authority (SHA), and Saskatchewan Cancer Agency (SCA) are launching a genome testing program to improve the safety of Saskatchewan cancer patients receiving chemotherapy treatment.
Patients eligible for treatment with fluoropyrimidine-based drugs who may face severe or life-threatening side effects can now have in-province DPYD genotyping done before starting their treatment. This test identifies genetic variants in the DPYD gene, which affects the production of the DPD (dihydropyrimidine dehydrogenase) enzyme.
"Screening for these genetic variants can help improve treatment outcomes for Saskatchewan cancer patients," Health Minister Everett Hindley said. "The introduction of DPYD genome testing shows our commitment to both precision medicine and patient safety. By making this a standard part of oncology practice, health-care providers can better manage treatment plans and potential complications."
Previously, DPYD testing was done in the U.S. with a two-week turnaround time. Now, the Royal University Hospital Pharmacogenomic Lab in Saskatoon is offering the test locally, with results in 2 to 7 days. The lab expects to test around 1,000 patients annually.
"Conducting rapid testing for DPD enzyme deficiencies right here in Saskatchewan helps our teams provide safer and more effective care as quickly as possible for cancer patients across the province, by appropriately adjusting their care plans before they receive treatment," SHA Provincial Clinical and Support Services Vice President Bryan Witt said. "This is a positive step in continuing to explore innovative solutions that improve patient-centred outcomes and reaffirms our commitment to advancing personalized medicine."
"Offering screening for DPD enzyme deficiency in Saskatchewan is one way we are ensuring cancer patients have access to the highest standard of care," Saskatchewan Cancer Agency Medical Services Vice-President Dr. Shazia Mahmood said. "Fluoropyrimidine based chemotherapy drugs are commonly used to treat multiple cancers, and DPD enzyme deficiency can lead to severe life-threatening toxicities in some patients. The Cancer Agency is pleased this testing will be offered to patients who are at risk in our ongoing efforts to ensure patient safety."
This initiative marks a significant advancement in cancer care, with Saskatchewan becoming the fourth province to implement DPYD testing. It aligns with global best practices and ensures our health care remains at the forefront of cancer treatment innovation.
-30-
We need your feedback to improve saskatchewan.ca. Help us improve
